OncoTarget® 500
Comprehensive Genomic Profiling Panel
Available in 7-10 business days
505 Total Genes Whole Exon
Clear insights to therapy options
What is OncoTarget®500?
OncoTarget® 500 integrates the robust bioinformatics of PGDx Elio Tissue Complete and provides physicians and researchers with medically actionable analyses on hundreds of cancer-related genes to help determine the specific genomic profile of an individual tumor. Based on the unique genomic profile of each patient's cancer, our test provides physicians with clinically actionable information to consider appropriate therapies for each patient and identify resistance to those therapies.

PD-L1 immunohistochemistry (IHC) testing is performed with a wide range of monoclonal antibodies. Results for microsatellite instability and tumor mutational burden are used to inform immunotherapy decisions, as well as many other actionable mutations.

FFPE samples are stained with H&E and reviewed by board-certified pathologists for tumor areas. A macro-dissection is performed to enrich the tumor content by no less than 20%.

Patients with qualifying Medicare or Medicare Advantage can receive OncoTarget® 500 across all solid tumors via Palmetto LCD.
505 Total Genes Whole Exon
505 SNVs And Indels
28 Amplifications
20 Translocations
2 Genomic Signatures
Cleared For All Solid Malignant Neoplasms
Clinical Values
of OncoTarget® 500
Available in 7-10 business days
  • Turn-key, automated bioinformatics with machine learning
  • Optimized workflow, processing begins immediately
505-genes tested
  • Assay developed from 30+ validation studies
  • For all solid tumors
  • Clinical pass rate of 92.9%
  • Guidance for immune therapy
Clear insights to therapy options
  • 100% clinical biomarkers covered
  • Includes a comprehensive list of CDx, NCCN guideline-directed targeted genes
  • 505 gene targeted whole-exome sequencing
7-10 Day Turnaround Time
Achieved by our streamlined lab process and AI-assisted bioinformatics pipeline
Actionable report delivered
Library prep
Pathologist review & sign out
DNA Extraction
Automated Bioinformatics
Next-Generation Sequencing
Step 1. DNA Extraction.
Step 2. Library prep
Step 7. Actionable report delivered
Step 3. Hybrid-capture
Step 5. Automated Bioinformatics
Step 4. Next-Generation Sequencing
Step 6. Pathologist review & sign out
Step 5.
Step 2.
Step 6.
Step 3.
Step 7.
Step 4.
Step 1.
First FDA-Cleared IVD Comprehensive
Genomic Profiling Panel
First FDA Cleared CE-IVD Marked Comprehensive Kitted Solution with Bioinformatics
Streamlined Workflow, Fast and Reliable
Excellent Results By A Large Prospective Study with Leading Academic Center​
30+ Validation Studies
Excellent Sensitivity and Specificity
Cleared For All Solid Malignant Neoplasms
OncoTarget 500® is tissue-based, clinically, and analytically validated for all solid malignant neoplasms.

This panel provides tumor mutation profiling information on somatic alterations (SNVs, small insertions and deletions, one amplification and four translocations), microsatellite instability (MSI) and tumor mutation burden (TMB) for use by qualified healthcare professionals in accordance with professional guidelines in oncology for previously diagnosed cancer patients.
Genes with FDA-Cleared Common Malignancies
OncoTarget®500 Sample Report of Colon Cancer
OncoTarget®500 Sample Report of Breast Cancer
OncoTarget®500 Sample Report of Lung Cancer
Sample Reports
Additional Testing Available
Three different tests to determine cancer risk – PROSTATENOW™ – Germline test for prostate cancer, BRCANOW® – Hereditary test for breast and ovarian cancer -LYNCHNOW® – Screening to detect Lynch syndrome.
Testing for a diagnosis, therapy and monitoring of certain blood disorders including leukemia and lymphoma.
GoPath® Labs
Whether a patient is in remission or is currently undergoing treatment, the sooner cancer recurrence or metastasis is found, the sooner the patient can receive appropriate therapy and treatment.
Delivering the broadest, FDA-cleared Comprehensive Genomic Profiling for solid tumors.
Begin your journey. Our team is ready to get you started.